NasdaqGM:MAZEPharmaceuticals
Maze Therapeutics Raises Fresh Capital As R&D Plans And Valuation Diverge
Maze Therapeutics (NasdaqGM:MAZE) completed a sizable underwritten public offering of common stock and pre funded warrants.
The deal drew significant participation from both new and existing institutional investors.
Proceeds are earmarked to advance Maze Therapeutics' research and development programs focused on serious diseases.
Maze Therapeutics, trading at a recent share price of $25.81, has experienced sharp share price swings, with a 7 day return of an 8.1% decline and a 30 day return...